Table 5 Comparison of lipids and fatty acids with significant correlation between age groups and ischaemic stroke subtypes
From: Features of serum fatty acids in acute ischaemic stroke patients aged 50 years or older
Age Groups | |||||||||
|---|---|---|---|---|---|---|---|---|---|
50 = < Age < 65 (n = 32) | p | 65 = < Age < 80 (n = 91) | p | 80 = < Age (n = 68) | p | ||||
LAA_SVO (n = 25) 78.1% | CE_O (n = 7) 21.9% | LAA_SVO (n = 48) 52.7% | CE_O (n = 43) 47.3% | LAA_SVO (n = 29) 42.6% | CE_O (n = 39) 57.4% | ||||
Age (m ± SD) years | 58.0 ± 3.9 | 57.0 ± 5.2 | ns | 71.5 ± 4.3 | 73.1 ± 4.2 | ns | 84.4 ± 4.0 | 85.7 ± 4.9 | ns |
Lipids | |||||||||
T-CHO (m ± SD) mg/dl | 224.2 ± 39.9 | 177.3 ± 33.7 | 0.0083 | 211.3 ± 45.5 | 195.3 ± 34.3 | ns | 209.2 ± 36.2 | 189.2 ± 35.5 | 0.0269 |
TG (MD, IQR) mg/dl | 173, 104–223 | 57, 48–180 | 0.034 | 93.5, 72.3–134 | 90, 67–134 | ns | 100, 66.5–138.5 | 86, 70.5–107 | ns |
Saturated Fatty Acids | |||||||||
LaA (C12:0) (MD, IQR) μg/ml | 1.8, 0.95–4.35 | 1.1, 0.3–1.7 | 0.068 | 1,2, 0.73–2.38 | 1,2, 0.7–2.6 | ns | 1.0, 0.65–2.2 | 1.1, 0.8–1.6 | ns |
MyA (C14:0) (MD, IQR) μg/ml | 23.9, 16.35–39.55 | 13, 11.7–22.5 | 0.0425 | 18.3, 13.73–27.73 | 17.6, 14–27.2 | ns | 18.2, 13.0–30.95 | 17.5, 12.4–22.1 | ns |
PA (C16:0) (MD, IQR) μg/ml | 777.8, 704.5–960.5 | 661.6, 535.1–718.4 | 0.024 | 679.95, 573.48–814.28 | 674.4, 597–833.1 | ns | 728, 586.95–776.7 | 621.4, 577–700.3 | 0.0153 |
StA (C18:0) (MD, IQR) μg/ml | 229.4, 208.6–280.05 | 168.6, 137.3–195.9 | 0.0051 | 209.25, 186.7–240.88 | 201.1, 174.2–243.4 | ns | 185.6, 176.25–224.9 | 184.3, 160.9–212.1 | ns |
n-9 Monounsaturated Fatty Acid | |||||||||
OlA (C18:1) (MD, IQR) μg/ml | 742.5, 637.45–865.85 | 601.8, 496.5–640.1 | 0.0381 | 602.65, 516.78–716.73 | 604.8, 506–793.4 | ns | 593.9, 499.35–692.75 | 541.1, 491.5–618.6 | ns |
OlA (C18:1) (m ± SD) % | 22.1 ± 2.37 | 23.2 ± 2.5 | ns | 21.36 ± 2.58 | 21.26 ± 2.28 | ns | 20.51 ± 2.19 | 20.79 ± 2.68 | ns |
n-6 Polyunsaturated Fatty Acids | |||||||||
LiA (C18:2) (MD, IQR) μg/ml | 896.8, 806.4–1007.75 | 697.5, 586.2–882.2 | 0.0213 | 804.35, 687.48–999.63 | 833.7, 698.4–932.7 | ns | 777.3, 666.85–866.1 | 664, 619.9–728.5 | 0.0182 |
DGLA (C20:3) (MD, IQR) μg/ml | 36.8, 28.9–48.35 | 22, 14.9–36.9 | 0.0448 | 31.7, 24.23–37.3 | 28.3, 18.6–36.1 | ns | 27.4, 21.45–36 | 23.1, 19.6–28 | 0.0252 |
AA (C20:4) (MD, IQR) μg/ml | 172.4, 146.4–204.5 | 116.4, 106.2–161 | 0.0189 | 147.0, 130.8–175.4 | 144.4, 113.1–158.9 | ns | 153, 123.85–172.25 | 133.1, 116.2–157.5 | 0.0401 |
DGLA (C20:3) (m ± SD) % | 1.08 ± 0.23 | 0.99 ± 0.33 | ns | 1.04 ± 0.29 | 0.93 ± 0.27 | ns | 1.03 ± 0.31 | 0.91 ± 0.20 | ns |
n-3 Polyunsaturated Fatty Acids | |||||||||
AlA (C18:3) (MD, IQR) μg/ml | 23.3, 19.05–31.4 | 21.8, 13.7–26.3 | ns | 21.7, 15.3–32.93 | 24, 16.4–32.5 | ns | 19.0, 14.15–25.45 | 17.3, 13.3–22.4 | ns |
EPA (C20:5) (MD, IQR) % | 1.43, 0.965–2.845 | 1.93, 0.61–2.74 | ns | 2.055, 1.50–2.835 | 2.22, 1.65–3.26 | ns | 2.23, 1.595–3.845 | 2.54, 1.92–3.37 | ns |
DHA (C22:6) (m ± SD) % | 3.956 ± 1.35 b | 3.60 ± 1.36 ab | ns | 4.515 ± 1.458 | 4.64 ± 1.26 | ns | 5.05 ± 1.19 | 5.21 ± 1.18 | ns |
EPA / AA ratio (MD, IQR) | 0.32, 0.19–0.53 | 0.35, 0.15–0.54 | ns | 0.455, 0.325–0.578 | 0.46, 0.37–0.67 | ns | 0.43, 0.305–0.725 | 0.48, 0.38–0.7 | ns |
n-6 / n-3 ratio (MD, IQR) | 4.72, 3.625–7.255 | 5.11, 3.97–7.81 | ns | 4.49, 3.448–5.625 | 4.3, 3.38–5.18 | ns | 4.03, 3.045–4.98 | 3.73, 2.91–4.55 | ns |